Clinical Trials
29 trialsNCT04640623 2026-06-05
SunRISe-1
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04658862 2026-06-05
SunRISe-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05567185 2026-06-05
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
NCT05714202 2026-06-05
SunRISe-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05891171 2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT06257264 2026-06-05
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT03132922 2026-06-04
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Phase 1 Active not recruiting
NCT04566393 2026-06-04
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT04960709 2026-06-04
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT06760819 2026-06-04
panSOHO
Bayer
Phase 2 Recruiting
NCT07421700 2026-06-04
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Recruiting
NCT07217171 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Phase 1 Recruiting
NCT07218380 2026-06-03
FORAGER-2
Eli Lilly and Company
Phase 3 Recruiting
NCT06940648 2026-06-02
VIABLE
Virtuoso Surgical, Inc.
Phase NA Enrolling by invitation
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT07144319 2026-05-29
ENAiBLE
Photocure
Recruiting
NCT07419295 2026-05-29
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03682068 2026-05-28
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT03924856 2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06833073 2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07038928 2026-05-28
RIVERS
AstraZeneca
Recruiting
NCT06225596 2026-05-27
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2 Active not recruiting
NCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT05614739 2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1 Recruiting
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT05951179 2026-05-18
ADVANCED-2
Protara Therapeutics
Phase 2 Recruiting
NCT06172478 2026-05-15
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 2 Recruiting